A Peptide‐Drug Conjugate‐Based Nanoplatform for Immunometabolic Activation and In Situ Nerve Regeneration in Advanced‐Stage Alzheimer's Disease
Advanced Materials · 2024-11 · 36 (46)
DOI: 10.1002/adma.202408729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 26.09.2024. Verfasst von Peixin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurob…. Hauptthemen laut MEDLINE: Alzheimer Disease, Nerve Regeneration, Peptides, Microglia. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Science and Technology Major Project.
Themen: Demenz
Abstract (Originalsprache)
The formidable protection of physiological barriers and unclear pathogenic mechanisms impede drug development for Alzheimer's disease (AD). As defenders of the central nervous system, immune‐metabolism function, and stemness of glial cells remain dormant during degeneration, representing a significant challenge for simultaneously targeting and modulating. Here, a modular nanoplatform is presented composed of peptide‐drug conjugates and an inflammation‐responsive core. The nanoplatform is transported through the blood‐brain barrier via transcytosis and disassembles in the oxidative stress microenvironment upon intravenous administration. The released drug‐conjugated modules can specifically target and deliver hydroxychloroquine (HCQ) and all‐trans retinoic acid (ATRA) to microglia and astrocytes, respectively. The immune function of chronic tolerant microglia is activated by metabolic modulation, and reactive astrocytes trans‐differentiate into functional neurons. In a transgenic mouse model, nanoplatform reduces levels of toxic proteins and inflammation while increasing neuronal density. This results in the amelioration of learning and memory decline. The modular nanoplatform provides design principles for multi‐cellular targeting and combination nano‐therapy for inflammation‐related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, S…
- Department of Digestive Diseases, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China.
ORCID-Profile: Chen Jiang
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Major Project
Zitieren
APA
Liu, P., Zhang, T., Wu, Y., Chen, Q., Sun, T., & Jiang, C. (2024). A Peptide‐Drug Conjugate‐Based Nanoplatform for Immunometabolic Activation and In Situ Nerve Regeneration in Advanced‐Stage Alzheimer's Disease. Advanced Materials, 36(46). https://doi.org/10.1002/adma.202408729
Vancouver
Liu P, Zhang T, Wu Y, Chen Q, Sun T, Jiang C. A Peptide‐Drug Conjugate‐Based Nanoplatform for Immunometabolic Activation and In Situ Nerve Regeneration in Advanced‐Stage Alzheimer's Disease. Advanced Materials. 2024;36(46). doi:10.1002/adma.202408729
BibTeX
@article{Liu2024,
author = {Liu, Peixin and Zhang, Tongyu and Wu, Yuxing and Chen, Qinjun and Sun, Tao and Jiang, Chen},
title = {A Peptide‐Drug Conjugate‐Based Nanoplatform for Immunometabolic Activation and In Situ Nerve Regeneration in Advanced‐Stage Alzheimer's Disease},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {46},
doi = {10.1002/adma.202408729}
}
EUVIMED